Results 171 to 180 of about 35,228 (288)

m5C‐Modified tRF3b‐CysGCA‐23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4

open access: yesAdvanced Science, EarlyView.
In this study, we identified an NSUN6‐dependent m5C‐modified tsRNA, m5C‐tRF3b CysGCA‐23 (mtRC), that is downregulated in BC and inversely correlated with disease progression. Mechanistically, mtRC suppresses BC malignancy by stabilizing RBM4, attenuating glycolysis, and thereby limiting H3K18 lactylation–mediated activation of IL1RAP and VASH2 ...
Xiaoling Ying   +16 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens. [PDF]

open access: yesCancer Immunol Immunother, 2023
Parikh AY   +13 more
europepmc   +1 more source

POU2F1 Promotes Chemoresistance in Colorectal Cancer Cells via Attenuates the MDR2 Degradation Mediated by PPP1R11 Lactylation

open access: yesAdvanced Science, EarlyView.
Schematic diagram of our study showing that highly expressed POU2F1 in colorectal cancer (CRC) can directly accelerate the cytosolic lactate export to decrease PPP1R11 lactylation at K59, thereby attenuating the E3 ligase enzyme activity and protein stability of PPP1R11, which inhibits the ubiquitination of MDR2 at K413 and K538 but increases the ...
Longzheng Xia   +8 more
wiley   +1 more source

Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel

open access: yesVirology Journal
Background Cervical squamous cell carcinoma (CSCC) is a prevalent gynecological malignancy worldwide. Current treatments for CSCC can impact fertility and cause long-term complications, underscoring the need for new therapeutic strategies.
Yanzhen Lin   +10 more
doaj   +1 more source

Development‐based In Vivo Bioreactor Strategy for Challenging Senescent Bone Reconstruction

open access: yesAdvanced Science, EarlyView.
We present a development‐based in vivo bioreactor strategy to generate rejuvenated bone grafts (vBR‐Bone) within aged hosts. By enclosing vBR‐Bone fragments within an asymmetric biomimetic periosteum, segmental femoral defects in aged mice were successfully repaired within 6 weeks. Mechanistically, the multifactors of vBR‐Bone reconstitute a remodeling
Wenchao Zhang   +9 more
wiley   +1 more source

Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment

open access: yes, 2020
Berger, H.   +13 more
core   +1 more source

Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery. [PDF]

open access: yesDis Colon Rectum, 2023
Wang T   +11 more
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy

open access: yesAdvanced Science, EarlyView.
This study utilizes programmable mechanical pressure as a therapeutic enhancer to establish a mechano‐chemotherapy strategy. Controlled pressure activates the mechanosensitive ion channel Piezo1 in bladder cancer, triggering a calcium ion cascade that transiently and reversibly amplifies membrane permeability to chemotherapeutics.
Minghai Ma   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy